Role of Type 2 Diabetes in Determining Retinal, Renal, and Cardiovascular Outcomes in Women With Previous Gestational Diabetes Mellitus.

COMMENTED

Type 2 Diabetes

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Lancet.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS

doi: 10.1016/S0140-6736

COMMENTED

Type 2 DiabetesDiabetes and Pregnancy

Lactation Duration and Long-term Risk for Incident Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Diabetes Care.

Ley SH, Chavarro JE, Li M, Bao W, Hinkle SN, Wander PL, Rich-Edwards J, Olsen S, Vaag A, Damm P, Grunnet LG, Mills JL, Hu FB, Zhang C

doi: 10.2337/dc19-2237.

COMMENTED

Type 2 Diabetes

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis

Diabetes Obes Metab.

Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine M, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V

doi: 10.1111/dom.

Diabetes - GeneralType 2 Diabetes

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Diabetologia.

Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B

doi: 10.1007/s00125-018-4644-9.

Diabetes - GeneralType 2 Diabetes

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®

Diabetologia.

Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, Fitchett D; EMPA-REG OUTCOME® investigators

doi: 10.1007/s00125-018-4630-2.

Diabetes - GeneralType 2 Diabetes

Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

J Am Heart Assoc.

Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Køber L

doi: 10.1161/JAHA.116.004743.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study

Diabetologia.

Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Scardapane M, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group

doi: 10.1007/s00125-018-4691-2.

COMMENTED

Type 2 Diabetes

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators

doi: 10.1056/NEJMoa1812389.

Diabetes - GeneralType 2 Diabetes

Determinants of 20-year non-progression to Type 2 diabetes in women at very high risk: the E3N cohort study

Diabet Med.

Fagherazzi G, Gusto G, Mancini FR, Dow C, Rajaobelina K, Balkau B, Boutron-Ruault MC, Bonnet F

doi: 10.1111/dme.13774.

Related content

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Lactation Duration and Long-term Risk for Incident Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®

Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Determinants of 20-year non-progression to Type 2 diabetes in women at very high risk: the E3N cohort study